Analysts Set Expectations for Innate Pharma FY2029 Earnings

Key Points

• HC Wainwright raised Innate Pharma’s FY2029 earnings forecast to $0.30 per share from $0.23 and projects FY2030 earnings of $0.61 per share. The firm maintains a “Buy” rating.
• Analyst sentiment is broadly positive, with five Buy ratings and one Sell rating, resulting in a consensus “Moderate Buy” rating and an average price target of $6.67.
• Innate Pharma shares opened at $1.86, compared with a 52-week range of $1.17 to $2.71. The biotechnology company is developing cancer immunotherapies, including lacutamab.

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA - Free Report) - Equities research analysts at HC Wainwright raised their FY2029 earnings estimates for shares of Innate Pharma in a report released on Monday, September 21st. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of $0.30 per share for the year, up from their previous forecast of $0.23. HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Innate Pharma's current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Innate Pharma's FY2030 earnings at $0.61 EPS.

IPHA has been the topic of a number of other reports. Citigroup upgraded shares of Innate Pharma from a "buy" rating to an "outperform" rating in a report on Tuesday, August 11th. BTIG Research reissued a "buy" rating and issued a $9.00 price objective on shares of Innate Pharma in a research report on Thursday, September 17th. Leerink Partners upgraded shares of Innate Pharma from a "market perform" rating to an "outperform" rating and set a $4.00 price objective on the stock in a research note on Tuesday, August 11th. UBS Group reaffirmed a "buy" rating on shares of Innate Pharma in a report on Tuesday, August 11th. Finally, Weiss Ratings raised shares of Innate Pharma from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, June 26th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $6.67.

Innate Pharma Price Performance

Shares of NASDAQ IPHA opened at $1.86 on Tuesday. Innate Pharma has a 52 week low of $1.17 and a 52 week high of $2.71. The stock has a 50 day moving average price of $1.98 and a 200 day moving average price of $1.75.

Innate Pharma Company Profile

Innate Pharma SA is a biotechnology company headquartered in Marseille, France, focused on developing immunotherapies for cancer. Founded in 1999, the company uses its expertise in the biology of natural killer cells and other components of the innate immune system to develop antibody-based treatments designed to help the immune system recognize and attack cancer cells.

Innate Pharma's pipeline includes lacutamab, an investigational antibody targeting KIR3DL2 for certain forms of cutaneous T-cell lymphoma and other T-cell malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.